Candida auris is a multidrug-resistant yeast which has emerged in healthcare facilities worldwide, however little is known about identification methods, patient colonization, spread, environmental survival, and drug resistance. Colonization on both biotic and abiotic surfaces, along with travel, appear to be the major factors for the spread of this pathogen across the globe.
INTRODUCTION
Candida auris, a multidrug-resistant pathogenic yeast has emerged in healthcare facilities across the globe. Candida auris was first described as a new species in 2009 from the ear discharge of a hospitalized patient in Japan (1) . In the last decade, cases of C. auris have been reported from 18 countries on five continents including Asia, Africa, Europe, South America, and North America (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Fungemia caused by C. auris is associated with a high mortality rate and therapeutic failure (13) . Ecological niches of C. auris remain unknown. However, successful colonization of human body sites and survival and persistence on surfaces within healthcare environments may be contributing to the outbreak and prevalence of C. auris worldwide. Whole genome sequence analyses of clinical C. auris isolates indicated that the emergence of clonal populations in Asia, South Africa, and South America occurred independently and spread locally within each region (7, 14, 15) .
The identification of C. auris has been challenging for most clinical laboratories because of reliance on biochemical-based identification systems such as VITEK 2 and API 20C AUX.
Due to the lack of C. auris in the database, these systems have misidentified it as C. haemulonii (5, 7, 9, 11, 14, 16) . Other less commonly used biochemical platforms also misidentified C. auris as Rhodotorula glutinis, C. famata, C. sake, and Saccharomyces cerevisiae (16) (17) (18) . Accurate identification of C. auris requires matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (19) or sequencing of the 18S ribosomal gene (1) . These reliable techniques are not readily available in most clinical laboratories. In the United States, the Food and Drug Administration (FDA) only recently approved the use of C. auris on the MALDI-TOF MS platform such as Bruker Daltonik, Bremen, Germany on April 24, 2018 (http://www.cidrap.umn.edu/news-perspective/2018/04/fda-approves-rapid-diagnostic-testcandida-auris), and bioMérieux VITEK MS, Marcy L'Etoile, France on December 21, 2018 (https://www.rapidmicrobiology.com/news/new-fda-clearance-for-vitek-ms-expanded-id-forchallenging-pathogens).
Apart from the difficult identification of C. auris, antifungal resistance testing has also been challenging. Approximately 90% of C. auris isolates are resistant to fluconazole (14) .
Moreover, elevated minimum inhibitory concentrations (MIC) for voriconazole have been reported for 50% of isolates, and higher MICs for amphotericin B for 30% of isolates (15, 16, 20) . Resistance to echinocandins although low, has also been reported (20) .
Adams and colleagues described the first 51 clinical cases and 61 colonized cases in the outbreak affecting in New York healthcare facilities (16) . As part of an ongoing response to this C. auris outbreak 540 clinical isolates and 11,035 patient and 3,762 environmental surveillance samples have been collected in New York from 2016 through 2018. Here we provide the laboratory analysis of these specimens which highlight the application of rapid molecular screening to outbreak control, the unique characteristics of C. auris isolates, the spectrum of antifungal resistance, and the prevalence of other pathogenic yeasts.
Materials and Methods

Sample collection and case definitions.
Clinical yeast isolates suspected of C. auris received from various healthcare facilities in NY from August 2016 to December 2018 were part of this investigation. However, surveillance samples (patient and environmental) collected from August 2016 to October 2018 from patients and their environment in various C. auris-affected healthcare facilities in NY were the major focus of these studies. Clinical cases were defined as the identification of a first C. auris isolate recovered from a specimen obtained to diagnose or treat disease (16) . Colonized cases were defined as the recovery of the first C. auris isolate recovered from a sample for surveillance purposes (16) . The environmental samples processed in this study were classified as porous (e.g. linen, carpet, etc.) and non-porous (e.g. metal knob, phone, TV monitor, bed rail, etc.) based on surface texture. A small percentage of environmental objects (2.8%) did not clearly fall within one of those two categories (e.g. chair, sofa, etc.) and were excluded from this study.
Candida identification. Candida isolates were speciated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker, Bremen, Germany) using both the manufacturer and in-house validated library databases. The in-house library database was enriched by adding spectra of several C. auris isolates from the current NY outbreak and from the Centers for Disease Control and Prevention-Antibiotic Resistance (CDC AR) bank (https://www.cdc.gov/drugresistance/resistance-bank/index.html).
Colonization study. Sample types: Axilla, groin, and nares swabs were collected individually or as a composite swab (axilla/groin or nares/axilla/groin) using the BD ESwab ™ Liquid Amies Collection and Transport System (Becton Dickinson, Franklin Lakes, NJ, USA) from patients in various healthcare facilities. Occasionally, rectal or other body site swabs or body fluids were also collected. For environmental sampling, various objects and surfaces in healthcare facilities were swabbed with 3M Sponge Sticks (3M Health Care, St. Paul, MN, USA), and after an area was sampled, the sponge was removed from the collection stick and placed in zip-top bag. All surveillance swabs, other body fluids, and environmental sponges were transported to the laboratory within 48 to 72 hours at ambient temperature.
Culture of swabs and sponges. Each ESwab containing 1 ml modified liquid Amies medium was vortexed for 30 seconds, and 50 μl was inoculated onto non-selective (Sabouraud dextrose agar containing antibacterials; SDA-A) and selective (Sabouraud dulcitol agar containing antibacterials and 10% salt; SDulA-AS) media as described previously (16) . Two hundred microliters of the ESwab liquid were also inoculated in selective broth media minus agar mediaminus agar (SDulB-AS). Sputum and bronchial aspirates were streaked on all the media as described above. Urine samples if received in large volume (10 to 20 ml), were concentrated by centrifugation at 4000 RPM for 5 min; supernatant was decanted leaving about 3 ml; 100 μl was inoculated onto both SDA-A and SDulA-AS plates, and 1 ml was inoculated in 5 ml of SDulB-AS broth.
Each environmental sponge sample was placed in a Whirl-Pak Homogenizer Blender
Filter bag containing 45 mL of phosphate-buffered saline (PBS) with 0.02% Tween 80. The bags were gently mixed in the Stomacher 400 Circulator (Laboratory Supply Network, Inc., Atkinson, NH, USA) at 260 rpm for 1 min, and the suspension was transferred into a 50-ml conical tube and centrifuged at 4,000 rpm for 5 min; supernatant was decanted, leaving about 3 ml of liquid at the bottom of the tube. The 3 mL liquid was vortexed briefly and of these 1 ml was removed, centrifuged, washed and re-suspended in 50 μl of PBS-BSA for DNA extraction as described below for swabs. From remaining 2 ml of liquid, 100 μl each was inoculated on SDA-A and SDulA-AS plates, and 1 ml was inoculated in 5 ml of SDulB-AS broth.
Agar plates and broth tubes were incubated at 40 o C for a maximum of two weeks.
Enumeration of colony forming units (CFU).
To determine the extent of colonization on skin by C. auris, the colonies recovered on the plates were counted. If colonies were numerous, a 10-fold dilution series of the swab was prepared and plated for colony counts. initial denaturation at 95°C for 3 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at 68°C for 3 min and the final extension at 68°C for 10 min. The PCR amplicons were sequenced, assembled, and edited using Sequencher 5.0 software (Gene Codes Corp., Ann Arbor, MI, USA) and BLAST searched against two databases: GenBank (www.ncbi.nlm.nih.gov/) and CBS-KNAW (www.cbs.knaw.nl/). Multiple alignments of ITS and D1/D2 sequences of C. auris from the current outbreak and reference strains were done using the Geneious R9 version 9.1.6 (Biomatters, Inc., Newark, NJ) and the phylogenetic analysis of the aligned sequences was done using the neighbor-joining (NJ) method with 2,000 bootstrap replicates on the same software. 
RESULTS
New York state-wide Candida auris identification.
We received 540 isolates of yeasts suspected of being C. auris from various clinical, public, and commercial laboratories. Of these, 413 were confirmed as C. auris, 12 as C. duobushaemulonii, and 7 as C. haemulonii (Supplementary Table   1 ). The remaining 108 isolates were confirmed as other yeasts (data not shown). In most cases, there was no correlation seen between presumptive identification (ID) by the requesting laboratory and the method they used for identification. Laboratories using ITS sequencing provided a 100% correct identification of C. auris (42/42) while laboratories using Bruker MALDI provided a 72% (106/147) correct identification. Laboratories using the VITEK MS provided 21% (9/43) correct identification of C. auris. Interestingly, some clinical laboratories using the biochemical-based system, VITEK 2 provided a presumptive C. auris identification.
Whether these laboratories presumed identification of C. haemulonii as C. auris or used a 'research use only' database of MALDI-TOF from Bruker or Biomerieux is unclear.
Clinical cases.
A total of 277 clinical cases were confirmed by culture during this period. The majority of C. auris isolates from clinical cases were recovered from blood (51%) followed by urine (23%) and then other body sites (Table 1 ). Based on these results, a blood stream infection Of 624 surveillance samples cultured, 450 were positive defining 350 colonized cases (Table 3 ). Although first positive surveillance sample defining 350 colonized cases originated from different body sites, we chose axilla/groin and nares to understand the probability and the extent of C. auris colonization as they made up the bulk of surveillance samples. Of 222 axilla/groin samples tested, 178 (80%) were positive for C. auris while of 215 nares samples tested, 125 (58%) were positive for C. auris (Table 3 ). When the extent of C. auris colonization in 178 axilla/groin and 125 nares positive sites were analyzed randomly; nares harbored 2 logs (P<0.001) higher C. auris than the axilla/groin (Fig. 1A) . When 74 of axilla/groin and nares in parallel (from same patient) were analyzed; nares harbored 2 logs higher C. auris than the axilla/groin (Fig. 1B) . These results indicated that axilla/groin is the preferred site of C. auris colonization as compared to nares in the colonized patients, but if nares is colonized, it harbors relatively higher burden of C. auris than axilla/groin. These results plus practical logistic and resource issues prompted us to use one composite swab of nares/axilla/groin for determining colonized cases, effective January 2018 for all point prevalence studies. Of 350 colonized cases, 106 were indeed identified using one composite swab of nares/axilla/groin in the present investigation.
Utility of C. auris real-time PCR assay in patient surveillance screening
Following NYSDOH CLEP approval of C. auris real-time PCR assay for patient surveillance samples effective May 2017, a total of 9,982 patient samples were tested from May 2017 to October 2018, and 6,834 of those samples were cultured as part of point prevalence studies. In comparison to culture as a gold standard, the diagnostic accuracy, sensitivity and specificity of the real-time PCR assay was 98.36%, 93.32% and 98.38%, respectively ( Table 4 A). The performance was consistent with findings in our earlier investigation (21) . ' Amplification of the D1/D2 region revealed a 500-bp amplicon and following sequencing and trimming of 5' and 3' primed ends, a 426-bp sequence was used for the multiple alignment.
Utility of C. auris real-time
There were two mutations at position 372 and 389 of T to C, and an insertion at position 392 and 393 of two Ts in South Asia clade I versus East Asia clade II. The topology of the neighbor joining tree was similar to that of ITS ( Fig. 3B ). Interestingly, all urine isolates from this patient collected on different days were resistant to echinocandins, but isolates recovered from other body sites were variably resistant or susceptible (Table 6 ) indicating the possibility of presence of heterogenous populations. None of the isolates recovered either for colonized patients or from the environment showed any resistance to echinocandins (i.e., echinocandin resistance was only identified in patients meeting the clinical case definition).
Analysis
Isolation of other fungal species from patient and environmental surveillance samples.
We determined what other organisms were present in the patient and environmental surveillance samples. Candida albicans (13.94%) was by far the dominant pathogen in patient surveillance samples followed by C. auris (9.54%), C. glabrata (6.49%), C. tropicalis (3.98%) and C. parapsilosis (3.76%). Several other rare Candida spp., other yeasts, molds, and bacterial species were also isolated ( Fig. 4 A) . The environmental samples were predominantly positive for C. parapsilosis (7.03%) followed by C. auris (5.42%), C. albicans (2.27%), C. guilliermondii (2.1%), and C. glabrata (1.61%). Other Candida species, yeast, molds, and bacteria were also isolated ( Fig. 4 B) .
DISCUSSION
Candida species are major causes of healthcare-associated infections in the United States (22) . Infections by these pathogens result in mortality rates of >30-40% and are responsible for the highest total annual hospitalization costs of any invasive fungal disease (n = 26,735; total cost $1.4 billion) (22) (23) (24) . The recent emergence of multidrug-resistant (MDR) C. auris has further exacerbated this crisis (9, 16) However, these calculations rely on culture as the gold standard, but this is not an appropriate comparator for environmental samples. For example, we did not know how long C. auris was present in the healthcare environment prior to sample collection. Also, several environmental samples received for testing were often collected after the site had been cleaned and disinfected.
The ability of real-time PCR assay to pick up DNA from live, dead and growth defective C. auris as well as its ability to pick up leftover DNA stuck to the objects likely impacted the calculated diagnostic accuracy. Nevertheless, environmental testing contributed substantially to the institution of infection control practices in the affected healthcare facilities. We would recommend that while PCR is an excellent screening tool for testing of environmental samples, culture should be used as the basis for follow up remediation efforts.
Despite extensive efforts, the outbreak is ongoing. This could be due to the complexity of the healthcare systems in the city including density and close proximity of healthcare facilities in the region, and/or the lack of testing availability within facilities. The Wadsworth Center Mycology Laboratory has taken on the burden of essentially all testing since the beginning of the outbreak, and the volume by itself is a limiting factor in the assessment of an outbreak of this magnitude. It is imperative that more clinical, public, and commercial laboratories adopt C. auris testing technologies. Additionally, there is an urgent need for the development of high throughput assays as well as point-of-care molecular tests for the rapid turnaround time of lab testing.
The phylogenetic data using ITS and D1/D2 regions of the ribosomal genes revealed that the South Asia clade I was the major genotype and the East Asia clade II was a minor genotype of the C. auris outbreak in NY. These results are consistent with whole genome sequencing results reported for NY strains (25) . The distinct separation of South and East Asia clades by ribosomal gene sequencing in the present study is encouraging as next generation sequencing technologies are not in widespread use by clinical, public, and commercial laboratories for fungal pathogens. Interestingly, we did not find any isolate of the South Africa Clade III or the South America Clade IV in NY despite being a large international port of entry. The current method of phylogenetic analysis with ribosomal genes is well established for the separation of Among colonized patients, the nares appeared to serve as an excellent site for C. auris growth as it harbored an approximately 2-logs higher CFU than the axilla/groin. The precise mechanism(s) leading to the extensive colonization of nares is currently unclear, but results of this investigation led us to use one combination swab of nares/axilla/groin rather than a separate individual swab for colonization screening, an approach necessary to handle an outbreak of this magnitude. Further research is needed to understand the mechanism(s) of colonization.
Although, C. auris recovery from the patient's skin and healthcare environment have been established previously (8, 9, 16) , in this report, we have used a quantitative approach to determine the extent of C. auris colonization of skin and mucosal surfaces of the colonized patients and their surrounding environment.
The resistance to fluconazole, voriconazole, and amphotericin B observed in the current outbreak was higher than the two large studies previously published (15, 20) and this discrepancy could be due to the fact that C. auris outbreak in NY was dominated by South Asia Clade I. South Asia Clade I was intrinsically resistant to fluconazole and approximately 81% of these isolates had elevated MIC to voriconazole and 61% to amphotericin B. The echinocandin resistance was noted in fewer isolates, which was consistent with other studies (15, 20) . Panresistance is always a concern in C. auris, and despite the large outbreak, we found only three isolates suspected to have pan-resistance based on testing done at the Wadsworth Center Mycology Laboratory with one isolate ultimately confirmed as pan-resistance at the CDC's Mycotic Diseases Branch. Our MIC values for two suspected pan-resistant isolates that did not confirm were 1.5 while CDC's Mycotic Diseases Branch reported them to be lower than 1.5.
There are more data emerging that indicate that amphotericin B resistance is inducible and transient, and MIC values of some isolates decrease following passage in the laboratory (26) .
Amphotericin B resistance is rare in most of the Candida species and it is thought to be associated with a fitness cost (27) . In contrast, closely related species to C. auris, C.
haemulonii, C. duobushaemulonii and C. pseudohaemulonii have high-level intrinsic resistance to amphotericin B (20) and therefore possibly a contributing factor to rare infections worldwide.
The borderline resistance observed in C. auris against amphotericin B is intriguing and suggests it has the ability to overcome fitness costs in order to survive, spread and cause infection worldwide. More research is needed to understand the mechanisms leading to amphotericin B resistance in C. auris. In our investigation, we have found a small percentage of isolates showing resistance to 5-flucytosine, which is indicative of either the patient having received combination therapy of amphotericin B and 5-flucytosine or the spread of resistant isolates in the healthcare facilities. Nevertheless, fewer isolates showing echinocandin or 5-FC resistance among the many isolates tested in the current outbreak clearly indicate that these isolates did not spread extensively in the healthcare facilities. More studies are needed to understand the impact of resistance on the fitness and survival of the isolates.
In summary, use of a real-time PCR assay as a rapid detection tool, quantification of the extent of colonization of C. auris on biotic (patient) and abiotic (environment) surfaces, successful use of one combination swab of nares/axilla/groin to combat the large outbreak of C. auris in New York, and the use of ribosomal genes to determine relatedness among C. auris isolates were among some of the highlights of this investigation and provide further insight into the C. auris outbreak in NY. colonized patients (Sur), environmental surfaces (Env), and 10 standard isolates from the CDC-AR bank were aligned. The neighbor joining method was used to construct the phylogenetic tree.
The bootstrap scores are based on 2,000 reiterations. The outbreak was predominately the South Asia Clade I with a minor population of the East-Asia Clade II. A tree representing a few C.
auris isolates from each group is shown. Note, ITS could not distinguish South Africa Clade III (CDC AR) from South Asia Clade I. parapsilosis. Other Candida species, and other yeasts were minor components. 
